scispace - formally typeset
Journal ArticleDOI

Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.

Reads0
Chats0
TLDR
The aim of this study was to examine the Australian/New Zealand experience of serious infections and TB in IBD patients receiving anti‐TNF‐α therapy from 1999–2009.
Abstract
Ian C Lawrance, Graham L Radford-Smith, Peter A Bampton, Jane M Andrews, Pok-Kern Tan, Anthony Croft, Richard B Gearry and Timothy H J Florin

read more

Citations
More filters
Journal ArticleDOI

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

TL;DR: The therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.
Journal ArticleDOI

Infection risk associated with anti-TNF-α agents: a review

TL;DR: Patients who are at high risk of herpes zoster reactivation would benefit from a second vaccination in adulthood when receiving TNF-α inhibitors and the strategies for mitigating against the development of these serious adverse events are discussed.
References
More filters
Journal ArticleDOI

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy

TL;DR: The rate of TB is not increased in RA patients generally and among infliximab-treated patients, the rate is 52.5 cases, and a thorough medical history regarding TB, as well as tuberculin testing and radiographic examination (if indicated), should be an essential component of anti-tumor necrosis factor therapy.
Journal ArticleDOI

Optimizing anti-TNF treatment in inflammatory bowel disease

TL;DR: Trial data suggest that systematic maintenance with 8 weekly doses of infliximab decreases the rate of complications, hospitalizations, and surgeries and these effects probably are achieved thanks to thorough healing of the bowel.
Journal ArticleDOI

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

TL;DR: Long-term infliximab treatment had a good overall safety profile in the patient cohort studied, with no difference between the two groups in mortality, malignancies and infection rate.
Journal ArticleDOI

Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.

TL;DR: There is a dose-related relationship between prednisone use and pneumonia risk in rheumatoid arthritis and this data call into question the belief that low-doseprednisone is safe.
Related Papers (5)